DentalCare Logo

Adjunctive and Prophylactic Use of Antibacterial Agents in Dentistry

Course Number: 475

PDF

References / Additional Resources

  1. Hallman M. The surfactant system protects both fetus and newborn. Neonatology. 2013;103(4):320-6. doi: 10.1159/000349994. Epub 2013 May 31.

  2. Lederberg J. Infectious history. Science. 2000 Apr 14;288(5464):287-93.

  3. [Darveau RP, McFall-Ngai M, Ruby E, et al. Host tissues may actively respond to beneficial microbes. ASM News 2003;69(4):186-191.](Darveau RP, McFall-Ngai M, Ruby E, et al. Host tissues may actively respond to beneficial microbes. ASM News 2003;69(4):186-191.)

  4. Brito LC, Sobrinho AP, Teles RP, et al. Microbiologic profile of endodontic infections from HIV- and HIV+ patients using multiple-displacement amplification and checkerboard DNA-DNA hybridization. Oral Dis. 2012 Sep;18(6):558-67. doi: 10.1111/j.1601-0825.2012.01908.x. Epub 2012 Feb 15.

  5. Uzel NG, Teles FR, Teles RP, et al. Microbial shifts during dental biofilm re-development in the absence of oral hygiene in periodontal health and disease. J Clin Periodontol. 2011 Jul;38(7):612-20. doi: 10.1111/j.1600-051X.2011.01730.x. Epub 2011 Apr 13.

  6. Haug RH. Microorganisms of the nose and paranasal sinuses. Oral Maxillofac Surg Clin North Am. 2012 May;24(2):191-6, vii-viii. doi: 10.1016/j.coms.2012.01.001. Epub 2012 Feb 14.

  7. McClelland R. Gram’s stain: The key to microbiology. Medical Laboratory Observer.2001;33(4):20-28.

  8. Kasmar AG, Hooper D. Pharmacology of bacterial infections: cell wall synthesis. In Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd Ed, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2008.

  9. Kuriyama T, Karasawa T, Nakagawa K, et al. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):600-8. doi: 10.1067/moe.2000.109639.

  10. Pennisi E. A mouthful of microbes. Science. 2005 Mar 25;307(5717):1899-901. doi: 10.1126/science.307.5717.1899.

  11. Warnke PH, Becker ST, Springer IN, et al. Penicillin compared with other advanced broad spectrum antibiotics regarding antibacterial activity against oral pathogens isolated from odontogenic abscesses. J Craniomaxillofac Surg. 2008 Dec;36(8):462-7. doi: 10.1016/j.jcms.2008.07.001. Epub 2008 Aug 29.

  12. Baker KA, Fotos PG. The management of odontogenic infections. A rationale for appropriate chemotherapy. Dent Clin North Am. 1994 Oct;38(4):689-706.

  13. Gill Y, Scully C. Orofacial odontogenic infections: review of microbiology and current treatment. Oral Surg Oral Med Oral Pathol. 1990 Aug;70(2):155-8.

  14. Greenberg RN, James RB, Marier RL, et al. Microbiologic and antibiotic aspects of infections in the oral and maxillofacial region. J Oral Surg. 1979 Dec;37(12):873-84.

  15. Heimdahl A, von Konow L, Satoh T, et al. Clinical appearance of orofacial infections of odontogenic origin in relation to microbiological findings. J Clin Microbiol. 1985 Aug;22(2):299-302.

  16. Kannangara DW, Thadepalli H, McQuirter JL. Bacteriology and treatment of dental infections. Oral Surg Oral Med Oral Pathol. 1980 Aug;50(2):103-9.

  17. Könönen E, Nyfors S, Mättö J, et al. beta-lactamase production by oral pigmented Prevotella species isolated from young children. Clin Infect Dis. 1997 Sep;25 Suppl 2:S272-4.

  18. Moenning JE, Nelson CL, Kohler RB. The microbiology and chemotherapy of odontogenic infections. J Oral Maxillofac Surg. 1989 Sep;47(9):976-85.

  19. Newman MG. Anaerobic oral and dental infection. Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S107-14.

  20. Sandor GK, Low DE, Judd PL, et al. Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc. 1998 Jul-Aug;64(7):508-14.

  21. Sands T, Pynn BR, Katsikeris N. Odontogenic infections: Part two. Microbiology, antibiotics and management. Oral Health. 1995 Jun;85(6):11-4, 17-21, 23 passim.

  22. van Winkelhoff AJ, Winkel EG, Barendregt D, et al. beta-Lactamase producing bacteria in adult periodontitis. J Clin Periodontol. 1997 Aug;24(8):538-43.

  23. von Konow L, Nord CE, Nordenram A. Anaerobic bacteria in dentoalveolar infections. Int J Oral Surg. 1981 Oct;10(5):313-22.

  24. Williams RC. Periodontal disease. N Engl J Med. 1990 Feb 8;322(6):373-82. doi: 10.1056/NEJM199002083220606.

  25. Avila M, Ojcius DM, Yilmaz O. The oral microbiota: living with a permanent guest. DNA Cell Biol. 2009 Aug;28(8):405-11. doi: 10.1089/dna.2009.0874.

  26. Barclay JK. Antibiotics revisited. N Z Dent J. 1990 Apr;86(384):44-7.

  27. Baumgartner JC. Microbiologic aspects of endodontic infections. J Calif Dent Assoc. 2004 Jun;32(6):459-68.

  28. Loesche WJ. The antimicrobial treatment of periodontal disease: changing the treatment paradigm. Crit Rev Oral Biol Med. 1999;10(3):245-75.

  29. Patel M, Chettiar TP, Wadee AA. Isolation of Staphylococcus aureus and black-pigmented bacteroides indicate a high risk for the development of Ludwig's angina. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Nov;108(5):667-72. doi: 10.1016/j.tripleo.2009.06.033.

  30. Siqueira JF Jr, Rôças IN, Alves FR, et al. Bacteria in the apical root canal of teeth with primary apical periodontitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 May;107(5):721-6. doi: 10.1016/j.tripleo.2009.01.042.

  31. Tomazinho LF, Avila-Campos MJ. Detection of Porphyromonas gingivalis, Porphyromonas endodontalis, Prevotella intermedia, and Prevotella nigrescens in chronic endodontic infection. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):285-8. Epub 2006 Sep 26. doi: 10.1016/j.tripleo.2006.05.010.

  32. Harbison H, Rose HS, Coen DM, et al. Principles of antibacterial and antineoplastic pharmacology. In Golan DE. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd Ed, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2008.

  33. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999 Feb;74(2):187-95. doi: 10.4065/74.2.187.

  34. US National Library of Medicine. DailyMed. Amoxicillin - amoxicillin capsule. Amoxicillin - amoxicillin tablet, film coated. Amoxicillin - amoxicillin tablet, chewable. Amoxicillin - amoxicillin suspension. Ranbaxy Pharmaceuticals Inc. Updated 5/2008. Accessed May 20, 2021.

  35. US National Library of Medicine. DailyMed. Cefaclor - cefaclor capsule. Alvogen, Inc. Updated 3/11. Accessed May 20, 2021.

  36. US National Library of Medicine. DailyMed. Cephalexin - cephalexin capsule. Cephalexin - cephalexin suspension. Ranbaxy Pharmaceuticals Inc. Accessed May 20, 2021.

  37. US National Library of Medicine. DailyMed. Penicillin V Potassium - penicillin v potassium tablet. Sandoz Inc. Accessed May 20, 2021.

  38. US National Library of Medicine. DailyMed. Vancocin - vancomycin hydrochloride capsule. Akorn, Inc. Accessed May 20, 2021.

  39. US National Library of Medicine. DailyMed. Vancomycin hydrochloride- vancomycin hydrochloride injection, solution. Baxter Healthcare Corporation. Accessed May 20, 2021.

  40. Wilhelm MP, Estes L. Symposium on antimicrobial agents--Part XII. Vancomycin. Mayo Clin Proc. 1999 Sep;74(9):928-35.

  41. Wright AJ. The penicillins. Mayo Clin Proc. 1999 Mar;74(3):290-307. doi: 10.4065/74.3.290.

  42. Baumgartner JC, Xia T. Antibiotic susceptibility of bacteria associated with endodontic abscesses. J Endod. 2003 Jan;29(1):44-7. doi: 10.1097/00004770-200301000-00012.

  43. Edson RS, Rosenblatt JE, Lee DT, et al. Recent experience with antimicrobial susceptibility of anaerobic bacteria: increasing resistance to penicillin. Mayo Clin Proc. 1982 Dec;57(12):737-41.

  44. Hackman AS, Wilkins TD. Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol. 1976;21(6):385-9.

  45. Handal T, Olsen I. Antimicrobial resistance with focus on oral beta-lactamases. Eur J Oral Sci. 2000 Jun;108(3):163-74.

  46. Heimdahl A, von Konow L, Nord CE. Isolation of beta-lactamase-producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections. Arch Oral Biol. 1980;25(10):689-92.

  47. Kinder SA, Holt SC, Korman KS. Penicillin resistance in the subgingival microbiota associated with adult periodontitis. J Clin Microbiol. 1986 Jun;23(6):1127-33.

  48. Murray PR, Rosenblatt JE. Penicillin resistance and penicillinase production in clinical isolates of Bacteroides melaninogenicus. Antimicrob Agents Chemother. 1977 Apr;11(4):605-8.

  49. Thaler DS. The evolution of genetic intelligence. Science. 1994 Apr 8;264(5156):224-5.

  50. Walker C, Gordon J. The effect of clindamycin on the microbiota associated with refractory periodontitis. J Periodontol. 1990 Nov;61(11):692-8. doi: 10.1902/jop.1990.61.11.692.

  51. Whitcher BL, Beirne OR, Smith RA. Beta-lactamase-producing Bacteroides melaninogenicus and osteomyelitis of the mandible. J Oral Med. 1983 Jan-Mar;38(1):17-20.

  52. Abbanat D, Morrow B, Bush K. New agents in development for the treatment of bacterial infections. Curr Opin Pharmacol. 2008 Oct;8(5):582-92. doi: 10.1016/j.coph.2008.08.001. Epub 2008 Sep 18.

  53. Ryou M, Coen DM. Pharmacologyof bacterial infections: DNA replication, transcription, and translation. In Golan DE, Tashjian, Jr. AH, Armstrong EJ, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd Ed, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.

  54. US National Library of Medicine. DailyMed. Avelox - moxifloxacin hydrochloride tablet, film coated. RedPharm Drug Inc. Accessed May 20, 2021.

  55. US National Library of Medicine. DailyMed. Cipro - ciprofloxacin hydrochloride tablet, film coated. Cipro - ciprofloxacin. Bayer HealthCare Pharmaceuticals Inc. Accessed May 20, 2021.

  56. US National Library of Medicine. DailyMed. Levaquin - levofloxacin tablet, film coated. Lake Erie Medical DBA Quality Care Products LLC. Accessed May 20, 2021.

  57. Walker RC. The fluoroquinolones. Mayo Clin Proc. 1999 Oct;74(10):1030-7. doi: 10.4065/74.10.1030.

  58. Al-Nawas B, Walter C, Morbach T, et al. Clinical and microbiological efficacy of moxifloxacin versus amoxicillin/clavulanic acid in severe odontogenic abscesses: a pilot study. Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):75-82. doi: 10.1007/s10096-008-0587-2. Epub 2008 Jul 29.

  59. Cachovan G, Böger RH, Giersdorf I, et al. Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. Antimicrob Agents Chemother. 2011 Mar;55(3):1142-7. doi: 10.1128/AAC.01267-10. Epub 2010 Dec 20.

  60. Ivers LC, Ryan ET. Pharmacology of parasitic infections. In Golan DE, Tashjian, Jr. AH, Armstrong EJ, et al. Principles of pharmacology: the pathophysiologic basis of drug therapy. 2nd Ed, Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008.

  61. US National Library of Medicine. DailyMed. Metronidazole - metronidazole tablet. Watson Labs. Accessed May 20, 2021.

  62. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc. 1999 Aug;74(8):825-33. doi: 10.4065/74.8.825.

  63. US National Library of Medicine. DailyMed. Sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet. Vista Pharmaceuticals, Inc. Accessed May 20, 2021.

  64. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999 Jul;74(7):727-9. doi: 10.4065/74.7.727.

  65. US National Library of Medicine. DailyMed. Doxycycline hyclate capsules - doxycycline hyclate capsule. Hikma Pharmaceutical. Accessed May 20, 2021.

  66. US National Library of Medicine. DailyMed. Minocin - minocycline hydrochloride capsule, coated pellets. Triax Pharmaceuticals, LLC. Accessed May 20, 2021.

  67. Czeizel AE, Rockenbauer M. A population-based case-control teratologic study of oral oxytetracycline treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2000 Jan;88(1):27-33.

  68. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. doi: 10.4065/74.5.519.

  69. US National Library of Medicine. DailyMed. Gentamycin sulfate - gentamicin sulfate injection, solution. Hospira, Inc. Accessed May 20, 2021.

  70. US National Library of Medicine. DailyMed. Clindamycin hydrochloride - clindamycin hydrochloride capsule. Cardinal Health. Accessed May 20, 2020.

  71. Ellison SJ. The role of phenoxymethylpenicillin, amoxicillin, metronidazole and clindamycin in the management of acute dentoalveolar abscesses--a review. Br Dent J. 2009 Apr 11;206(7):357-62. doi: 10.1038/sj.bdj.2009.257.

  72. Addy LD, Martin MV. Azithromycin and dentistry - a useful agent? Br Dent J. 2004 Aug 14;197(3):141-3; discussion 138. doi: 10.1038/sj.bdj.4811530.

  73. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc. 1999 Jun;74(6):613-34. doi: 10.4065/74.6.613.

  74. Al-Belasy FA, Hairam AR. The efficacy of azithromycin in the treatment of acute infraorbital space infection. J Oral Maxillofac Surg. 2003 Mar;61(3):310-6. doi: 10.1053/joms.2003.50063.

  75. McCracken GH Jr. Microbiologic activity of the newer macrolide antibiotics. Pediatr Infect Dis J. 1997 Apr;16(4):432-7.

  76. Moore PA. Dental therapeutic indications for the newer long-acting macrolide antibiotics. J Am Dent Assoc. 1999 Sep;130(9):1341-3.

  77. US National Library of Medicine. DailyMed. Azithromycin - azithromycin dihydrate tablet, film coated. Azithromycin - azithromycin dihydrate powder, for suspension. Greenstone LLC. Accessed May 20, 2021

  78. Walker CB. The acquisition of antibiotic resistance in the periodontal microflora. Periodontol 2000. 1996 Feb;10:79-88.

  79. Dirks SJ, Terezhalmy GT. The patient with an odontogenic infection. Quintessence Int. 2004 Jun;35(6):482-502.

  80. Lockhart PB, Tampi MP, Abt E, et al. Evidence-based clinical practice guideline on antibiotic use for the urgent management of pulpal- and periapical-related dental pain and intraoral swelling: A report from the American Dental Association. J Am Dent Assoc. 2019 Nov;150(11):906-921.e12. doi: 10.1016/j.adaj.2019.08.020.ADA.

  81. Hahn CL, Falkler WA Jr. Antibodies in normal and diseased pulps reactive with microorganisms isolated from deep caries. J Endod. 1992 Jan;18(1):28-31. doi: 10.1016/S0099-2399(06)81139-8.

  82. Huang GT, Potente AP, Kim JW, et al. Increased interleukin-8 expression in inflamed human dental pulps. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):214-20.

  83. Massler M, Pawlak J. The affected and infected pulp. Oral Surg Oral Med Oral Pathol. 1977 Jun;43(6):929-47.

  84. Matsushima K, Ohbayashi E, Takeuchi H, et al. Stimulation of interleukin-6 production in human dental pulp cells by peptidoglycans from Lactobacillus casei. J Endod. 1998 Apr;24(4):252-5. doi: 10.1016/S0099-2399(98)80107-6.

  85. Rauschenberger CR, Bailey JC, Cootauco CJ. Detection of human IL-2 in normal and inflamed dental pulps. J Endod. 1997 Jun;23(6):366-70. doi: 10.1016/S0099-2399(97)80184-7.

  86. Torneck CD. A report of studies into changes in the fine structure of the dental pulp in human caries pulpitis. J Endod. 1981 Jan;7(1):8-16.

  87. Oguntebi BR, DeSchepper EJ, Taylor TS, et al. Postoperative pain incidence related to the type of emergency treatment of symptomatic pulpitis. Oral Surg Oral Med Oral Pathol. 1992 Apr;73(4):479-83.

  88. Keenan JV, Farman AG, Fedorowicz Z, et al. Antibiotic use for irreversible pulpitis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004969. doi: 10.1002/14651858.CD004969.pub2.

  89. Nagle D, Reader A, Beck M, et al. Effect of systemic penicillin on pain in untreated irreversible pulpitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):636-40. doi: 10.1067/moe.2000.109777.

  90. Brennan MT, Runyon MS, Batts JJ, et al. Odontogenic signs and symptoms as predictors of odontogenic infection: a clinical trial. J Am Dent Assoc. 2006 Jan;137(1):62-6.

  91. Ranta H, Haapasalo M, Ranta K, et al. Bacteriology of odontogenic apical periodontitis and effect of penicillin treatment. Scand J Infect Dis. 1988;20(2):187-92.

  92. Fouad AF, Rivera EM, Walton RE. Penicillin as a supplement in resolving the localized acute apical abscess. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 May;81(5):590-5.

  93. Cioffi GA, Terezhalmy GT, Parlette HL. Cutaneous draining sinus tract: an odontogenic etiology. J Am Acad Dermatol. 1986 Jan;14(1):94-100.

  94. Herrera D, Alonso B, de Arriba L, et al. Acute periodontal lesions. Periodontol 2000. 2014 Jun;65(1):149-77. doi: 10.1111/prd.12022.

  95. Bratton TA, Jackson DC, Nkungula-Howlett T, et al. Management of complex multi-space odontogenic infections. J Tenn Dent Assoc. 2002 Fall;82(3):39-47.

  96. Meislin HW. Pathogen identification of abscesses and cellulitis. Ann Emerg Med. 1986 Mar;15(3):329-32.

  97. Stone A, Straitigos GT. Mandibular odontogenic infection with serious complications. Oral Surg Oral Med Oral Pathol. 1979 May;47(5):395-400.

  98. Mark AA. Using antibiotics wisely. J Am Dent Assoc. 2019 Nov;150(11):986.

  99. Akimoto Y, Nishimura H, Komiya M, et al. Ampicillin concentrations in human serum and dental pulp following a single oral administration. J Nihon Univ Sch Dent. 1984 Jun;26(2):148-54.

  100. Haas DA, Epstein JB, Eggert FM. Antimicrobial resistance: dentistry's role. J Can Dent Assoc. 1998 Jul-Aug;64(7):496-502.

  101. Heimdahl A, Nord CE. Treatment of orofacial infections of odontogenic origin. Scand J Infect Dis Suppl. 1985;46:101-5.

  102. Runyon MS, Brennan MT, Batts JJ, et al. Efficacy of penicillin for dental pain without overt infection. Acad Emerg Med. 2004 Dec;11(12):1268-71. doi: 10.1197/j.aem.2004.08.034.

  103. Meurman JH. Dental infections and general health. Quintessence Int. 1997 Dec;28(12):807-11.

  104. Harrison JW, Svec TA. The beginning of the end of the antibiotic era? Part II. Proposed solutions to antibiotic abuse. Quintessence Int. 1998 Apr;29(4):223-9.

  105. Gruchalla RS, Pirmohamed M. Clinical practice. Antibiotic allergy. N Engl J Med. 2006 Feb 9;354(6):601-9. doi: 10.1056/NEJMcp043986.

  106. Nord CE. Mechanisms of beta-lactam resistance in anaerobic bacteria. Rev Infect Dis. 1986 Nov-Dec;8 Suppl 5:S543-8.

  107. Lewis MA, Parkhurst CL, Douglas CW, et al. Prevalence of penicillin resistant bacteria in acute suppurative oral infection. J Antimicrob Chemother. 1995 Jun;35(6):785-91.

  108. US Department of Health & Human Services. FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. Accessed May 20, 2021.

  109. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet. 2007 Feb 10;369(9560):482-90. doi: 10.1016/S0140-6736(07)60235-9.

  110. Sandor GK, Low DE, Judd PL, et al. Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc. 1998 Jul-Aug;64(7):508-14.

  111. Chardin H, Yasukawa K, Nouacer N, et al. Reduced susceptibility to amoxicillin of oral streptococci following amoxicillin exposure. J Med Microbiol. 2009 Aug;58(Pt 8):1092-7. doi: 10.1099/jmm.0.010207-0. Epub 2009 Jun 15.

  112. Gordon J, Walker C, Hovliaras C, et al. Efficacy of clindamycin hydrochloride in refractory periodontitis: 24-month results. J Periodontol. 1990 Nov;61(11):686-91.

  113. Kuriyama T, Nakagawa K, Karasawa T, et al. Past administration of beta-lactam antibiotics and increase in the emergence of beta-lactamase-producing bacteria in patients with orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Feb;89(2):186-92. doi: 10.1067/moe.2000.102040.

  114. Gilmore WC, Jacobus NV, Gorbach SL, et al. A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections. J Oral Maxillofac Surg. 1988 Dec;46(12):1065-70.

  115. Hupp JR. Antibacterial, antiviral and antifungal agents. Oral Maxillofac Surg Clin North Am. 1991;3:273–285.

  116. Mangundjaja S, Hardjawinata K. Clindamycin versus ampicillin in the treatment of odontogenic infections. Clin Ther. 1990 May-Jun;12(3):242-9.

  117. von Konow L, Köndell PA, Nord CE, et al. Clindamycin versus phenoxymethylpenicillin in the treatment of acute orofacial infections. Eur J Clin Microbiol Infect Dis. 1992 Dec;11(12):1129-35.

  118. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008 Oct 30;359(18):1932-40. doi: 10.1056/NEJMra0707500.

  119. Sandor GK, Low DE, Judd PL, et al. Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc. 1998 Jul-Aug;64(7):508-14.

  120. Lodi G, Azzi L, Varoni EM, et al. Antibiotics to prevent complications following tooth extractions. Cochrane Database Syst Rev. 2021 Feb 24;2(2):CD003811. doi: 10.1002/14651858.CD003811.pub3. Accessed May 20, 2021.

  121. Singh GA, Morrissey H, Rahman A. A Systematic Review and Meta-Analysis Evaluating Antibiotic Prophylaxis in Dental Implants and Extraction Procedures. Medicina (Kaunas). 2018 Dec 1;54(6):95. doi: 10.3390/medicina54060095.

  122. Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of Viridans Group Streptococcal Infective Endocarditis: A Scientific Statement From the American Heart Association American Heart Association. Circulation. 2021 Apr 15:CIR0000000000000969. doi: 10.1161/CIR.0000000000000969.

  123. Watters W 3rd, Rethman MP, Hanson NB, et al. Prevention of Orthopaedic Implant Infection in Patients Undergoing Dental Procedures. J Am Acad Orthop Surg. 2013 Mar;21(3):180-9. doi:10.5435/JAAOS-21-03-180.

  124. Sollecito TP, Abt E, Lockhart PB, et al. The use of prophylactic antibiotics prior to dental procedures in patients with prosthetic joints: Evidence-based clinical practice guideline for dental practitioners--a report of the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2015 Jan;146(1):11-16.e8. doi: 10.1016/j.adaj.2014.11.012. Epub 2014 Dec 18.

  125. Huber MA, Terezhalmy GT. The patient with a transient bacteremia. Gen Dent. 2005 Mar-Apr;53(2):130-43; quiz 144-6.

  126. Lockhart PB, Loven B, Brennan MT, et al. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. J Am Dent Assoc. 2007 Apr;138(4):458-74; quiz 534-5, 437.

  127. Termine N, Panzarella V, Ciavarella D, et al. Antibiotic prophylaxis in dentistry and oral surgery: use and misuse. Int Dent J. 2009 Oct;59(5):263-70.

  128. Greenberg RN, James RB, Marier RL, et al. Microbiologic and antibiotic aspects of infections in the oral and maxillofacial region. J Oral Surg. 1979 Dec;37(12):873-84.

  129. James RB, Fredrickson C, Kent JN. Prospective study of mandibular fractures. J Oral Surg. 1981 Apr;39(4):275-81.

  130. Zallen RD, Curry JT. A study of antibiotic usage in compound mandibular fractures. J Oral Surg. 1975 Jun;33(6):431-4.

  131. Miles BA, Potter JK, Ellis E 3rd. The efficacy of postoperative antibiotic regimens in the open treatment of mandibular fractures: a prospective randomized trial. J Oral Maxillofac Surg. 2006 Apr;64(4):576-82. doi: 10.1016/j.joms.2006.01.003.

  132. Simo R, French G. The use of prophylactic antibiotics in head and neck oncological surgery. Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):55-61. doi: 10.1097/01.moo.0000193183.30687.d5.

  133. Brisson-Noël A, Arthur M, Courvalin P. Evidence for natural gene transfer from gram-positive cocci to Escherichia coli. J Bacteriol. 1988 Apr;170(4):1739-45.

  134. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992 Aug 21;257(5073):1050-5.

  135. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science. 1994 Apr 15;264(5157):375-82.

  136. Harrison JW, Svec TA. The beginning of the end of the antibiotic era? Part I. The problem: abuse of the "miracle drugs". Quintessence Int. 1998 Mar;29(3):151-62.

  137. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ. 1998 Sep 5;317(7159):657-60.

  138. Higgins NP. Death and transfiguration among bacteria. Trends Biochem Sci. 1992 Jun;17(6):207-11.

  139. Hughes VM, Datta N. Conjugative plasmids in bacteria of the 'pre-antibiotic' era. Nature. 1983 Apr 21;302(5910):725-6.

  140. Koshland DE Jr. The microbial wars. Science. 1992 Aug 21;257(5073):1021.

  141. Neu HC. The crisis in antibiotic resistance. Science. 1992 Aug 21;257(5073):1064-73.

  142. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University Workshop. N Engl J Med. 1994 Apr 28;330(17):1247-51. doi: 10.1056/NEJM199404283301725.

  143. Travis J. Possible evolutionary role explored for "jumping genes". Science. 1992 Aug 14;257(5072):884-5.

  144. Travis J. Reviving the antibiotic miracle? Science. 1994 Apr 15;264(5157):360-2.

  145. Trieu-Cuot P, Carlier C, Courvalin P. Conjugative plasmid transfer from Enterococcus faecalis to Escherichia coli. J Bacteriol. 1988 Sep;170(9):4388-91.

  146. Suda KJ, Calip GS, Zhou J, et al. Assessment of the Appropriateness of Antibiotic Prescriptions for Infection Prophylaxis Before Dental Procedures, 2011 to 2015. JAMA Netw Open. 2019 May 3;2(5):e193909. doi: 10.1001/jamanetworkopen.2019.3909.

  147. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med. 2012 May 17;366(20):1881-90. doi: 10.1056/NEJMoa1003833.

  148. Drug Information Handbook. 23rd ed. Hudson OH: Lexicomp Inc; 2014.

  149. Department of Health and Human Services, Food and Drug Administration. Content and Format of Labeling for Human Prescription Drug and Biological Products; Requirements for Pregnancy and Lactation Labeling. Federal Register / Vol. 79, No. 233 / Thursday, December 4, 2014 / Rules and Regulations. Accessed May 20, 2021.

  150. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000 Jul 13;343(2):118-26. doi: 10.1056/NEJM200007133430208.

  151. Kacew S. Adverse effects of drugs and chemicals in breast milk on the nursing infant. J Clin Pharmacol. 1993 Mar;33(3):213-21.

  152. Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series. J Am Dent Assoc. 1999 Feb;130(2):236-51.

  153. Meechan JG. Polypharmacy and dentistry: 2. Interactions with analgesics and antimicrobials. Dent Update. 2002 Oct;29(8):382-8. doi: 10.12968/denu.2002.29.8.382.

  154. Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002 Jun;46(6):917-23.

  155. LaCasa C. California court denies wrongful birth claim. J Law Med Ethics. 1996 Fall;24(3):273-4.

  156. Dickinson BD, Altman RD, Nielsen NH, et al. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001 Nov;98(5 Pt 1):853-60.

  157. Antibiotic interference with oral contraceptives. ADA Health Foundation Research Institute, Department of Toxicology. J Am Dent Assoc. 1991 Dec;122(12):79.

  158. ADA Council on Scientific Affairs. Antibiotic interference with oral contraceptives. J Am Dent Assoc. 2002 Jul;133(7):880.

Additional Resources


  • No Additional Resources Available
0/22Next